Trial reportAdvances in therapy2026
Medication Instruction and Mirogabalin Treatment Satisfaction in Patients with Neuropathic Pain due to Orthopedic Diseases: Results of MiroSearch, a Japanese Exploratory Interventional Study.
Trial report in Advances in therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionWe postulateded that providing medication instruction to patients with various orthopedic diseases and scheduled to receive mirogabalin would improve their satisfaction with treatment. The MiroSearch study investigated the impact of medication instruction on treatment satisfaction with mirogabalin.
methodsThis was a multicenter, open-label, exploratory, interventional study, conducted in Japan. The study included outpatients with mild to more severe neuropathic pain (NeP) (numerical rating scale [NRS] score 0-10) due to various orthopedic diseases. Patients received medication instruction for mirogabalin from a physician or pharmacist at baseline and week 4. The primary endpoint was patient treatment satisfaction with mirogabalin.
resultsOf the 201 patients who provided informed consent, 194 were included, and 166 completed the study. Patient treatment satisfaction (at least satisfied) at week 8 was 52.8% (86/163) (95% confidence interval [CI] 44.8-60.6%). Patient understanding at week 8 was associated with patient treatment satisfaction at week 8 (Cochran-Armitage test, p = 0.021 for trend). In cases in which physicians were satisfied or more with treatment at week 8, agreement rate between patient and physician treatment satisfaction at week 8 was 49.1% (80/163), and the disagreement rate was 30.1% (49/163). Patient satisfaction with communication with the physician was associated with patient treatment satisfaction. The NRS score for pain decreased from baseline to week 8 (change from baseline, - 2.0 [95% CI - 2.4, - 1.5], p < 0.001). Treatment-emergent adverse events occurred in 53.8% (105/195) of patients; most were mild or moderate in severity.
conclusionOver half of patients with NeP due to orthopedic diseases were satisfied with mirogabalin treatment. Medication instruction can improve patient understanding of their disease and medications and enhance their treatment satisfaction. Furthermore, communication between patients and physicians/pharmacists may contribute to improving patient treatment satisfaction. TRIAL REGISTRATION NUMBER: Japan Registry of Clinical Trials identifier, jRCTs041230059.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.